As a core drug in MG treatment, it reduces the release of proinflammatory factors by inhibiting the NF-kB signaling pathway while enhancing Treg cell function, thus performing superiorly in acute phase symptom control (31). This evidence concerns the gene NFKB1 and myasthenia gravis.